Market Overview

UPDATE: Barclays Maintains Penn Virginia at Underweight on 2013 Production Outlook

Related PVA
Penn Virginia Corporation Announces Borrowing Base Increase To $500M And Financial Liquidity In Excess Of $620M
Kite Pharmaceuticals Releases Positive Non-Hodgkin's Lymphoma Result; iKang Healthcare Disappoints

Barclays reiterated its Underweight rating and $5 price target on Penn Virginia (NYSE: PVA) as the quarterly production guidance declines.

Barclays noted, "Our UW rating reflects concern in achieving the 2013 production targets and continuing to fund the cash flow gap while relying almost entirely on the Eagle Ford play for growth. … Management issued FY13 production guidance of 34-37 Bcfe, an 8% decrease from its FY12 guidance of 38-39 Bcfe, partially due to asset sales. PVA expects oil production to grow 25% Y-o-Y and liquids production to comprise 55-65% of FY13 equivalent volumes. We are somewhat cautious on the guidance given the fact that oil volumes have been on a slower trajectory in 2012 with a similar capital program."

Penn Virginia closed at $4.41 on Tuesday.

Latest Ratings for PVA

DateFirmActionFromTo
Dec 2014BarclaysMaintainsEqual-weight
Dec 2014Imperial CapitalMaintainsOutperform
Nov 2014Credit SuisseMaintainsOutperform

View More Analyst Ratings for PVA
View the Latest Analyst Ratings

Posted-In: BarclaysAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (PVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters